MedTrace Logo

A Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression

NCT01098240 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 297

Last updated 2021-05-03

Study results available
· View outcomes & findings →

Summary

The primary objectives of this study are to: 1) Evaluate the efficacy of CP 601,927 compared to placebo in the augmentation of antidepressant therapy (ADT) in patients with Major Depressive Disorder (MDD) using the Montgomery Asberg Depression Rating Scale (MADRS). 2) Evaluate the safety and tolerability of CP 601,927 in patients with MDD on ADT.

Conditions

Interventions

DRUG

CP-601,927

CP-601,927 1-2 mg twice per day, oral 1 mg tablets, for 6 weeks.

OTHER

Placebo

Matching placebo tablets, taken orally, twice per day, for 6 weeks.

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-06-14
Primary Completion
2011-09-12
Completion
2011-09-12

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01098240 on ClinicalTrials.gov